medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2016, Number 1

Next >>

Arch Neurocien 2016; 21 (1)

Guillain-Barré syndrome. Experience with 91 Children at a Pediatric Hospital in Northwestern Mexico

Durán RA, Fonseca-Chon I, Sotelo-Cruz N

Language: English
References: 36
Page: 7-16
PDF size: 195.14 Kb.


ABSTRACT

Introduction: Guillain-Barré syndrome (GBS) is an acute, inflammatory, demyelinating polyradiculoneuropathy .
Objective: To describe the clinical course, treatment, and evolution in 91 children.
Methods: The variables were: age, gender, season, vaccines, disability grade, clinical variants, laboratory test, treatment, and evolution. JMP.SAS, software package.
Results: Most were males (p = 0.035). Preschooler age (42%), Seventy five percent of cases (p ‹0.0001) appeared during spring-summer; 5.4 %, received vaccines previously. Signs and symptoms: pain 48%, weakness 100%, high blood pressure 16%, Miller-Fisher variety 17%. By the Hughes scale at 48 h, 49% exhibited disability grade 4 (p ‹0.0001). Albumin-cytological dissociation 68%. Treatment, 39.5% received Intravenous immunoglobulin (IVIG), and their recovery in less time than with other treatments (p = 0.0478); ventilator assistance led to longer hospital stay (p ‹0.0001), and there was no mortality.
Discussion: GBS presentation was seasonal, and with the use of IVIG, the hospital stay was shorter.


REFERENCES

  1. Winer JB. Guillain-Barré syndrome: clinical variants and their pathogenesis. J Neuroimaging 2011;231:70-2.

  2. Ortez- González CI, Diaz - Conradi A. Síndrome de Guillain- Barré en la infancia. An Pediatr Contin 2013;11(29):98-103.

  3. Incecik F, Herguner MO, Altunbasak S. Guillain-Barré syndrome in children. Neurol Sci 2011;32;381.

  4. Zhong M. Cai FCH. Current perspectives on Guillain-Barré syndrome. World J Pediatr 2007;3(3):187-93.

  5. Monroy-Guerrero J, Núñez-Orozco L. Síndrome de Landry-Guillain-Barré-Strohl. Rev Mex Neuroci 2005;6(3):271-82.

  6. Hallett M, Tandon D, Berardelli A. Treatment of pheripheral neuropathies. J Neurol Neurosurg Psych 1985;48:1193-1207.

  7. Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre Syndrome. The Cochrane Data base System Rev. 2014;CD2063. Pub 6:Pub6:1-63.

  8. Hughes RAC, Wijdiks EFM, Barohn R, Benson E., Cornblath DR., Hahn AF, et al. Practice parameter. Immunotherapy for Guillain-Barré syndrome. Neurology 2003;61(2):736-40.

  9. Roodbol J, De Wit MCY, Walgaard C, Catsman-Berrevoets CE, Jacobs BC. Recognized Guillain-Barré syndrome in preschool children. Neurology 2011;76:807-810.

  10. JMP Pro. 11.0, SAS Institute. Inc. Cary, NC, USA.

  11. Lineamientos para la vigilancia epidemiológica de la parálisis flácida aguda y síndrome de Guillain-Barré posterior a la aplicación de la vacuna contra virus de la influenza. Secretaría de Salud (SSA), México. 2010; 6-25.

  12. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978;2:750-3.

  13. Barraquer-Bordás L, Neurología. En: Lain E, editor. Historia Universal de la Medicina. Vol. 7. Barcelona, España: Salvat, 1975:294-305.

  14. Korinthenberg R, Schessl J, Krischner J. Clinical presentation and course of childhood Guillain-Barré syndrome: a prospective multicentre study. Neuropediatrics 2007;38(1):10-7.

  15. Hardy TA, Blum S, McCombe PA, Reddel SW. Guillain-Barré syndrome: modern theories of etiology. Curr Allergy Asthma Rep 2011;11:197-204.

  16. Caudie C, Quittar-Pinon A, Taravel D, Sivadon-Tardy V, Orlikowski D, Rozenberg F, et al. Preceding infections and anti-ganglioside antibody profiles assessed by dot immunoassay in 306 French Guillain-Barré syndrome patients. J Neurol 2011;DOI 10.1007/s00415-011-6042-9.

  17. Poropatich KO, Fisher-Walker CL, Black RE. Quantifying the association between Campylobacter infection and Guillain-Barré syndrome: a systematic review. J Health Popul Nutr 2010;28(6):545-52.

  18. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011;36:123-33.

  19. Deeks SL, Lim GH, Simpson MA, Rosella L, Makie CO, Achonu C, Crowcroft NS. Estimating background rates of Guillain-Barré syndrome in Ontario in order to respond to safety concerns during pandemic H1N1/09 immunization campaign. BMC Public Health 2011;11:329. Doi:10.1186/1471-2458-11-329.

  20. Landaverde JM, Danovaro-Holliday MC, Trumbo SP, Pacis-Tirso, Ruiz-Matus C. Guillain-Barré syndrome in children aged <15 years in Latin America and the Caribbean: baseline rates in the context of the influenza A(H1N1) pandemic. J Infect Dis 2010;201:746-50.

  21. Nachamkin I, Arzate-Barbosa P, Ung H, González-Rivera A, Rodríguez P, García-Briseño A, et al. Patterns of Guillain-Barré syndrome in children. Results from a Mexican population. Neurology 2007;69:1665-71.

  22. González-Rivera A, Chico-Aldama P, Arzate-Barbosa P., Rodríguez-Pinto M., McKhann GM., Lobato C. Nahamkin I, et al. Epidemiología del síndrome de Guillain-Barré asociado a Campilobacter jejuni en el INP. Acta Pediatr Mex 2006;27(5):300-3.

  23. Walgaard C, Lingsma HF, Ruts L, Van- Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology 2011;76:968-75.

  24. Lal-Koul R, Alfutaisi A. Prospective study of children with Guillain-Barré syndrome. Indian J Pediatr 2008;75(8):787-90.

  25. Miller ER, Moro PL, Cano M, Simabukuro K. Deaths following vaccination: what does the evidence show? Vaccine 2015;33(29):3288-92.

  26. Anlar O, Tombul T, Arslan S, Akdeniz H, Cacksen H, Gundem A, Akbayram SW. Report of five children with Guillain- Barré syndrome following a nationwide oral polio vaccine campaign in Turkey. Neurol India 2003;51(4):544-5.

  27. Wilmshurst JM, Macleod MJ, Hughes E, Hughes RA. Acute sensory neuropathy in an adolescent girl following BCG vaccination. Eur J Paediatr Neurol 1999;3(6):227-9.

  28. Mori M, Kuwabara S. Fisher syndrome. Curr Treat Options Neurol 2011;13:71-8.

  29. Agrawal S, Peake D, Whitehouse WP. Management of children with Guillain-Barré syndrome. Arch Dis Child Edu Pract Ed 2007;92(6):161-8.

  30. Seikh KA, Zhang G. An update on pathobiologic roles of anti-glycan antibodies in Guillain-Barré syndrome. (Abstract). Biol Rep 2010;25(2):21.

  31. Guía práctica clínica. Diagnóstico y tratamiento del síndrome de Guillain-Barré, en el segundo y tercer nivel de atención. Consejo de Salubridad General. Centro Nacional de Excelencia Tecnológica (CENETEC). Secretaria de Salud (SSA). México, 2008. pp. 18-21.

  32. Merkies ISJ, Schimitz PIM, Vander Meché FGA, Samijin JPA, Van Doorn PA. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2002;72:596-601.

  33. Winters JL, Brown D, Hazard E, Chainani A, Chester A. Cost-minimization analysis of the direct costs of Therapeutic Plasma Exchange and intravenous immunoglobulin in the treatment of Guillain-Barré syndrome. BMC Health Services Res 2011;101. doi:10.1186/1472-6963-11.101.

  34. Pérez-Lledó E, Díaz- Vico, Gómez- Gosálvez FA. Síndrome de Guillain- Barre: presentación y evolución en menores de 6 años de edad. An Pediatr. 201276(2):69-76.

  35. Lin JJ, Hsia SH, Wang HS, Lin KL, Lyu RK. Risk factors and outcomes of Guillain-Barré syndrome with acute myelitis. Pediatr Neurol 2011;44(2):110-6.

  36. Lopate G. Pestronk A. Inflammatory demyelinating neuropathies. Curr Treat Options Neurol 2011;13(2):131-42.




2020     |     www.medigraphic.com